Europe Medicinal Chemistry for Drug Discovery Market is expected to grow with the CAGR of 13.7% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-medicinal-chemistry-for-drug-discovery-market

Europe medicinal chemistry for drug discovery market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Europe medicinal chemistry for drug discovery market are introducing strong range of services portfolio. This helped companies to maximize the sales with enhanced services portfolio.

For instance,

• In October 2020, Charles River and ATEM Structural Discovery (ATEM) announced the formation of a strategic partnership to provide clients access to ATEM’s cryo-electron microscopy (cryo-EM) service solutions. Cryo-EM is a technique that determines the 3D structures of proteins and is utilized to identify how proteins function, how they malfunction in disease, and the most effective way to target them with therapies. This will enhance the service portfolio of the company.

Eurofins Scientific Inc.,is dominating player in Europe medicinal chemistry for drug discovery market. The other key players existing in the market includes LabCorp Drug development, Charles River, Wuxi Apptec, Evotec SE, Piramal Pharma Solutions, Thermo Fisher Scientific Inc., Aurigene Pharmaceuticals Services, Aurelia Bioscience, BioBlocks Inc., Certara Inc., Genscript Biotech, Pfizer Inc., Selvita, Spectris PLC, Sygnature Discovery and Taros Chemical GMBH among others.

EUROFINS SCIENTIFIC INC.

Eurofins Scientific Inc., has headquartered in Luxembourg, Germany was founded in 1987. The company is engaged in the developments of Agro testings, Bio Pharma, Cosmetics and Personal care, Food and Feed testing and Forensic science. They combine insights from multiple data sources to drive more effective and efficient research and allow for better therapeutic decisions for patients.

• In February 2020, Eurofins Scientific Inc. acquired Beacon Discovery for its innovative approach, years of experience in drug discovery and development, and profound expertise in GPCR (G-Protein Coupled Receptor) research. This will help the company to increase its Europe presence.

The company has presence in North America and Europe. The company has various subsidiaries that are Eurofins Agro science services Pty Ltd., Eurofins Agro science testing Pty Ltd., Eurofins Agro science services Ltd a., Eurofins Belgium NV, Eurofins Environment Testing Canada Inc., and among others.

LABCORP DRUG DEVELOPMENT

LabCorp Drug Development headquartered in Burlington, North Caroline in USA was founded in year 1995. The company is engaged in products in Clinical laboratory business, end-to-end drug development, medical device and companion diagnostic, development solutions from early stage research to clinical development and commercial market access.– that help lead healthier lives.

• In December 2019, LabCorp Drug Development completed the acquisition of Toxikon Corporation. The addition of Toxikon to Labcorp Drug development boost Labcorp's strong expanding nonclinical development testing capabilities for pharmaceutical, biotech clients and creates a strategic footprint in drug development.

The company has wide Europe presence across the world as North America, Europe, Latin America, Africa, Asia Pacific with its various subsidiaries such as Litholink (Chicago), Esoterix Genetic Laboratories LLC (USA), MedTox (USA), Pathology Associates Medical Laboratories (PAML) (USA) among others.

CHARLES RIVER

Charles River headquartered in Wilmington, MA was founded in year 1947. The company is engaged in products in drug discovery, medicinal devices, Pharmaceuticals and Biotechnology industries– that help lead healthier lives.

• In May 2019, Charles River International announced that it had signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions. This will enhance the company’s Europe presence.

The company has wide Europe presence across the world as U.S., U.K., India and Australia with its subsidiaries such as HemaCare and Cellero are wholly owned subsidiaries.